X-ray powder diffraction data for 5-chloro-N-(4-(5, 6-dihydro-3-(4-morpholinyl)-2-oxo-1(2H)-pyridinyl)phenyl)-pentanamide, C20H26ClN3O3. Issue 2 (16th March 2016)

• Record Type: Journal Article
• Authors: Wang, Qing; Guo, Dan; Tang, Bin; Li, Hui
• Is Part Of: Powder diffraction. Volume 31:Issue 2(2016)
• Page Start: 159
• Page End: 161
• Publication Date: 2016-03-16
• Subjects: pharmaceutical intermediate, -- anticoagulant, -- apixaban; Powder metallurgy -- Periodicals; Materials -- Analysis -- Periodicals; 620.1127
• DOI: 10.1017/S0885715616000063
• Languages: English
• ISSNs: 0885-7156

Abstract

Abstract : Apixaban (Eliquis ® ) is a novel oral pyrazole-based direct FXa inhibitor. The title compound is an intermediate in the synthesis of the anticoagulant, Apixaban. X-ray powder diffraction data for the title compound, are reported [ a = 9.511(5) Å, b = 18.539(2) Å, c = 5.645(3) Å, α = 90°, β = 101.813(1)°, γ = 90°, unit-cell volume V = 974.28 Å 3, Z = 2, ρ cal = 1.336 g cm −3, and space group P 2]. All measured lines were indexed and are consistent with the P 2 space group. No detectable impurities were observed.